Pivotal bioVenture Partners Investment Advisor LLC
Follow13F filer, CIK 1844645, SAN FRANCISCO, CA
Pivotal bioVenture Partners Investment Advisor LLC reported $251,770,820 across 14 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-13. Its ten largest share positions make up 91.13% of the portfolio.
Accepted , ingested 13F-HR 0001012975-26-001045
- Period
- 2026-09-30
- Reported value
- $252M
- Holdings
- 14
- Top 10 weight
- 91.13%
- New
- 2
- Sold out
- 1
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| OBXnew | +860,343 | $11.8M |
| BRVEnew | +317,351 | $6.41M |
| OCSadded | +152,657 | $1.43M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| ZBIOreduced | -257,590 | -$6.95M |
| ARQTreduced | -257,109 | -$6.8M |
| AVLNreduced | -100,000 | -$2.85M |
| RXRXexited | -595,518 | -$2.19M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q3 2026
Share positions as resolved from 13F-HR 0001012975-26-001045, largest first. % of portfolio is the value over $251,770,820, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| PCVXVAXCYTE INC | 1,425,470 | $81.1M | 32.22% | 0 | Timeline | ||
| ARQTARCUTIS BIOTHERAPEUTICS INC | 1,008,174 | $26.6M | 10.58% | -257,109 | Timeline | ||
| TRVITREVI THERAPEUTICS INC | 1,742,672 | $25M | 9.91% | 0 | Timeline | ||
| AVLNAVALYN PHARMACEUTICALS INC | 866,792 | $24.7M | 9.81% | -100,000 | Timeline | ||
| EVMNEVOMMUNE INC | 1,926,943 | $15.9M | 6.32% | 0 | Timeline | ||
| IMNMIMMUNOME INC | 732,512 | $15.8M | 6.26% | 0 | Timeline | ||
| OCSOCULIS HOLDING AG | 1,658,907 | $15.5M | 6.15% | +152,657 | Timeline | ||
| OBXOBSIDIAN THERAPEUTICS INC | 860,343 | $11.8M | 4.69% | new | Timeline | ||
| AVTXAVALO THERAPEUTICS INC | 434,033 | $6.65M | 2.64% | 0 | Timeline | ||
| BRVEBRAVEHEART BIO INC | 317,351 | $6.41M | 2.55% | new | Timeline | ||
| ZBIOZENAS BIOPHARMA INC | 233,176 | $6.29M | 2.5% | -257,590 | Timeline | ||
| MPLTMAPLIGHT THERAPEUTICS INC | 611,446 | $6.23M | 2.47% | 0 | Timeline | ||
| RLYBRALLYBIO CORP | 300,579 | $5.17M | 2.05% | 0 | Timeline | ||
| BIOABIOAGE LABS INC | 653,374 | $4.63M | 1.84% | 0 | Timeline |
Sold out in Q3 2026
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| RXRXRECURSION PHARMACEUTICALS IN | 595,518 | $2.19M | shares |
How Q3 2026 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001012975-26-001045 | base | 2026-11-13 |